Xenon Pharmaceuticals Inc. (XENE) 8-K Summary
Filing Date: November 3, 2025
This 8-K serves primarily as notification that Xenon Pharmaceuticals Inc. released its financial results via press release for the:
- Three months ended September 30, 2025
- Nine months ended September 30, 2025
Investors must refer to Exhibit 99.1 for the actual financial performance metrics and operational updates, as this 8-K only announces the release of that information.
- Trading Symbol: XENE (Nasdaq Global Market)
- Management Signatory: Thomas P. Kelly, CFO.
- **Reg FD Note: